MetaVia (MTVA) Competitors $0.71 -0.03 (-4.29%) As of 07/25/2025 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. VTVT, AVTX, NRXP, ALGS, INMB, CELU, IPSC, SNTI, ZIVO, and JSPRShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include vTv Therapeutics (VTVT), Avalo Therapeutics (AVTX), NRx Pharmaceuticals (NRXP), Aligos Therapeutics (ALGS), INmune Bio (INMB), Celularity (CELU), Century Therapeutics (IPSC), Senti Biosciences (SNTI), ZIVO Bioscience (ZIVO), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors vTv Therapeutics Avalo Therapeutics NRx Pharmaceuticals Aligos Therapeutics INmune Bio Celularity Century Therapeutics Senti Biosciences ZIVO Bioscience Jasper Therapeutics MetaVia (NASDAQ:MTVA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment. Which has more volatility & risk, MTVA or VTVT? MetaVia has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Does the media prefer MTVA or VTVT? In the previous week, vTv Therapeutics had 1 more articles in the media than MetaVia. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for MetaVia. MetaVia's average media sentiment score of 1.89 beat vTv Therapeutics' score of 1.28 indicating that MetaVia is being referred to more favorably in the media. Company Overall Sentiment MetaVia Very Positive vTv Therapeutics Positive Is MTVA or VTVT more profitable? vTv Therapeutics' return on equity of -121.46% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -222.13% -123.85% vTv Therapeutics N/A -121.46%-46.75% Do institutionals and insiders hold more shares of MTVA or VTVT? 1.4% of MetaVia shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 4.2% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, MTVA or VTVT? vTv Therapeutics has higher revenue and earnings than MetaVia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/AvTv Therapeutics$1.02M48.26-$18.46M-$3.01-5.13 Do analysts prefer MTVA or VTVT? MetaVia presently has a consensus target price of $7.50, suggesting a potential upside of 963.68%. vTv Therapeutics has a consensus target price of $35.50, suggesting a potential upside of 130.07%. Given MetaVia's higher possible upside, analysts clearly believe MetaVia is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryvTv Therapeutics beats MetaVia on 8 of the 10 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.43M$3.05B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E RatioN/A21.1828.2320.08Price / SalesN/A282.17430.5089.23Price / CashN/A42.7636.2258.56Price / Book0.778.378.665.88Net Income-$27.59M-$55.19M$3.25B$258.72M7 Day Performance4.63%5.86%4.24%3.72%1 Month Performance3.69%17.29%10.51%11.73%1 Year PerformanceN/A4.39%34.43%18.02% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.2605 of 5 stars$0.71-4.3%$7.50+963.7%N/A$14.43MN/A0.008VTVTvTv Therapeutics1.54 of 5 stars$16.68-1.2%$35.50+112.9%-26.6%$53.28M$17K-5.549News CoveragePositive NewsAVTXAvalo Therapeutics3.3406 of 5 stars$4.90+2.0%$30.00+512.9%-42.5%$52.80M$440K0.0040News CoveragePositive NewsNRXPNRx Pharmaceuticals2.5358 of 5 stars$3.03-2.7%$28.50+842.1%+28.2%$52.48MN/A-1.512ALGSAligos Therapeutics4.306 of 5 stars$8.53+0.4%$70.00+720.6%-32.4%$52.12M$3.94M-0.4990News CoveragePositive NewsINMBINmune Bio1.9985 of 5 stars$2.18+5.1%$18.40+746.0%-68.0%$51.29M$10K-1.1310Positive NewsUpcoming EarningsCELUCelularity0.1409 of 5 stars$2.17-12.6%N/A-1.0%$51.11M$54.22M-0.81220News CoverageUpcoming EarningsIPSCCentury Therapeutics3.541 of 5 stars$0.59+2.4%$4.20+609.5%-73.7%$51.01M$6.59M-2.04170Positive NewsSNTISenti Biosciences2.2678 of 5 stars$1.95+3.7%$8.50+335.9%-16.8%$50.86M$2.56M-0.184ZIVOZIVO BioscienceN/A$13.28-1.6%N/A+30.2%$50.69M$15.85K-2.7210JSPRJasper Therapeutics3.7406 of 5 stars$3.36+1.4%$29.75+786.7%-85.2%$50.09MN/A-0.6420 Related Companies and Tools Related Companies VTVT Alternatives AVTX Alternatives NRXP Alternatives ALGS Alternatives INMB Alternatives CELU Alternatives IPSC Alternatives SNTI Alternatives ZIVO Alternatives JSPR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
